Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
February 18, 2020
Date of Patent:
May 4, 2021
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Juliane Sarah Walz, Daniel Johannes Kowalewski, Markus Loeffler, Moreno Di Marco, Nico Trautwein, Annika Nelde, Stefan Stevanovic, Hans-Georg Rammensee, Sebastian Haen
Abstract: A polypeptide is disclosed that binds tumor-associated antigens (TAA) on the surface of cancer cells and a NKG2D receptor. The NKG2D receptor is expressed on the surfaces of killer cells such as natural killer cells, T cells, natural killer T cells, and gamma delta T cells. In some cases, the TAA is CS-1 or EGFRvIII. Also disclosed are polynucleotides encoding the disclosed polypeptides, vectors comprising the disclosed polynucleotides, and host cells comprising the disclosed vectors. Also disclosed are bivalent antibodies comprising the disclosed polypeptides. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies. Also disclosed are methods of treating cancer in a subject using the disclosed bi-specific antibodies.
Type:
Grant
Filed:
February 22, 2016
Date of Patent:
April 13, 2021
Assignee:
OHIO STATE INNOVATION FOUNDATION
Inventors:
Jianhua Yu, Michael Caligiuri, Wing Keung Chan
Abstract: A control device generates a second command value by compensating a first command value output at every control cycle according to a predetermined pattern with a correction amount output at every control cycle according to correction data, updates the correction data based on a deviation between the first command value and a feedback value from the control object, and determines an initial value of the correction data. The control device acquires a response characteristic indicating a relationship between an assigned command value and a feedback value shown in the control object in response to the command value, estimates a feedback value to be shown in the control object based on a value obtained by compensating the first command value with temporary correction data and the response characteristic, and updates the temporary correction data based on a deviation between the first command value and the estimated feedback value.
Abstract: Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human MUC16 (monospecific antibodies) and antigen-binding fragments thereof. In some embodiments, the anti-MUC16 antibodies and the antigen-binding fragments thereof are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.
Type:
Grant
Filed:
September 22, 2017
Date of Patent:
March 9, 2021
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Lauric Haber, Eric Smith, Marcus Kelly, Jessica R. Kirshner, Sandra Coetzee, Alison Crawford, Thomas Nittoli, Yashu Liu
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
April 10, 2018
Date of Patent:
January 26, 2021
Assignee:
Immatics Biotechnologies GmbH
Inventors:
Juliane Sarah Walz, Daniel Kowalewski, Markus Löffler, Moreno Di Marco, Nico Trautwein, Annika Nelde, Stefan Stevanovic, Hans-Georg Rammensee, Sebastian Haen
Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy chain/light chain mispairing.
Type:
Grant
Filed:
March 20, 2017
Date of Patent:
October 27, 2020
Assignees:
Centre National de la Recherche Scientifique, Azienda socio sanitaria territoriale Papa Giovanni XXIII, Universite de Lausanne
Inventors:
Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay
Abstract: The present invention provides a recombinant fusion protein containing a first extracellular Ig-like domain of a signal-regulator protein alpha (SIRP?), linked to an Fc fragment of a human IgG1. The present invention also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of CD47.
Abstract: Provided are methods for identifying T-cell receptors that bind to an antigen in primates. In certain embodiments, the methods comprise: sequencing the cDNA prepared from a combined population of T-cells to obtain a plurality of T-cell receptor alpha chain sequences and a plurality of T-cell receptor beta chain sequences; grouping the obtained alpha chain sequences into alpha chain groups based on their CDR3 sequences; grouping the obtained beta chain sequences into beta chain groups based on their CDR3 sequences; pairing the alpha chain groups with the beta chain groups based on the number of alpha chain or beta chain sequences in each group; pairing one alpha chain sequence and one beta chain sequence in each paired alpha chain group and beta chain group; and testing candidate T-cell receptor comprising the paired alpha chain and beta chain sequences for binding to the antigen.
Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.
Type:
Grant
Filed:
April 24, 2018
Date of Patent:
October 6, 2020
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Birgit Bossenmaier, Hubert Kettenberger, Christian Klein, Klaus-Peter Kuenkele, Joerg-Thomas Regula, Wolfgang Schaefer, Manfred Schwaiger, Claudio Sustmann
Abstract: The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.
Type:
Grant
Filed:
January 14, 2016
Date of Patent:
September 1, 2020
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, INSTITUT REGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIER
Inventors:
Alain Couvineau, Thierry Voisin, Pascal Nicole, Bruno Robert, Pierre Martineau, Myriam Chentouf
Abstract: The disclosure relates to, among other things, agents that modulate the homophilic interaction between two CRACC polypeptides, methods for making such agents, and therapeutic applications in which the agents are useful. For example, the agents described herein are useful for modulating an immune response in a mammal. Also featured are screening methods for identifying additional agents capable of modulating the activation of an immune cell exposed to an antigen.
Type:
Grant
Filed:
September 22, 2015
Date of Patent:
August 25, 2020
Assignee:
Board of Trustees of Michigan State University
Abstract: Described is a bispecific antibody, and a method for producing the bispecific antibody. The bispecific antibody can be used in the preparation of a drug for treating a tumor with high cell expression of CD26. The antibody specifically hinds to human CD26 and human CD3 at the same time.
Type:
Grant
Filed:
October 30, 2015
Date of Patent:
August 25, 2020
Assignees:
ZONHON BIOPHARMA INSTITUTE INC., GENSUN INSTITUTE OF BIOMEDICINE CO., LTD.
Abstract: The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.
Type:
Grant
Filed:
August 11, 2017
Date of Patent:
July 28, 2020
Inventors:
Ozlem Tureci, Ugur Sahin, Sandra Schneider, Gerd Helftenbein, Volker Schluter, Dirk Usener, Philippe Thiel, Michael Koslowski
Abstract: Described herein are Fc variants and methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins). Heteromultimeric proteins may be capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.
Abstract: The present invention relates inter alia to therapeutic agents for use in the treatment of melanoma, methods of diagnosing an increased risk of metastasis in a subject suffering from melanoma, methods of treating such subjects, diagnostic assays and kits. More particularly, in certain embodiments the invention relates to identifying whether a subject suffering from melanoma has an increased risk of metastasis by determining the expression of Ambra-1 and Loricrin in a tissue sample obtained from the subject.
Abstract: The present invention relates to a carbonic anhydrase IX targeting compound for the use in the treatment of cancer, wherein the use comprises quantifying CAIX expression as well as the determination of a CAIX score based on the CAIX expression. The present invention relates further to a method for diagnosing, predicting and/or classifying a cancer disease comprising quantifying CAIX expression, and the determination of a CAIX score.
Type:
Grant
Filed:
February 21, 2014
Date of Patent:
April 14, 2020
Assignee:
Wilex AG
Inventors:
Olaf Wilhelm, Paul Bevan, Barbara Fall, Pia Klöpfer
Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
Type:
Grant
Filed:
November 20, 2017
Date of Patent:
April 14, 2020
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi
Abstract: The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.
Type:
Grant
Filed:
October 20, 2014
Date of Patent:
April 7, 2020
Assignee:
EPITOMICS, INC.
Inventors:
Fernando Jose Rebelo Do Couto, Kristin Beth Hendricks, Stacey Ellen Wallace, Guo-Liang Yu
Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.
Type:
Grant
Filed:
December 21, 2015
Date of Patent:
March 24, 2020
Assignees:
TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH, ASTELLAS PHARMA INC.
Inventors:
Ugur Sahin, Ozlem Tureci, Michael Koslowski, Rita Mitnacht-Kraus
Abstract: Multispecific antibodies that specifically bind at least two different epitopes are provided. Structural variants of native antibodies (antibody analogs) are also provided. Also provided are multispecific antibodies and antibody analogs having a range of biological activities. Agonist and antagonist multispecific antibodies and agonist and antagonist antibody analogs are provided. Multispecific antibodies and antibody analogs conjugated with therapeutic and/or diagnostic agents are also provided, as are multispecific antibodies and antibody analogs conjugated with agents to increase in vivo half-life compared to multispecific antibodies and antibody analogs lacking such agents. In addition, methods of making multispecific antibodies and antibody analogs and compositions comprising multispecific antibodies and antibody analogs are provided. Therapeutic, research, and diagnostic uses of multispecific antibodies and antibody analogs are also provided.